Ferring Acthrel to be launched in mid-summer; orphan drug is company's first U.S. approval.
FERRING ACTHREL DIAGNOSTIC TO BE LAUNCHED IN MID-SUMMER at an expected cost of $275 per treatment (one 100 mcg vial), the company said. Corticorelin ovine triflutate for injection was approved May 23 for "use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome." The orphan indication covers approximately 63,000 patients per year, Ferring said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth